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Abstract
Label free methods such as cell impedance assays are in vitro tests increas-
ingly used in drug development and producing large and high-content data files.
Since the current commercial software are not suited for fully automated anal-
ysis, there is a need to develop validated and rapid solutions to extract rele-
vant information for biologists. This need is particularly obvious in the case
of impedance signals analysis from cardiomyocytes. The proposed solution is
based on three main steps. The first one consists in calculating five indices
informing about the time variations of frequency (F), amplitude (A), shape (S)
of beatings, trends (T) of the cardiomyocyte dependent on spreading, viability
and attachment as well as irregularity (I) of the contractility. In a second phase,
two summary statistics are proposed to test the concentration effect of drugs on
the five FASTI indices. Results of the statistical tests are finally aggregated in
a cardio-effect grade to compare the tested molecules in a cardio-impact scale
graduated from 0 (no influence) to 10 (highly disturbed effects in cardiomy-
ocytes). This innovative approach was tested using in vitro data obtained from
cell impedance analysis of three known molecules (2 cardiotoxic and 1 non-
cardiotoxic compounds). Results have clearly shown the ability of the proposed
approach to identify significant effects on the contractility of cardiomyocytes.
This solution speeds up the analysis of cardiomyocyte impedance data, takes
into account all the kinetic data generated and is now available for biologists on
a web-platform: i-CardioTM developed by CYBERnanoTM.
Keywords: signal processing, biostatistics, high-content screening, impedance,
label-free technology, cardiomyocyte, cardiotoxicity.
Preprint submitted to Biomedical Signal Processing and Control October 8, 2017
1. Introduction
The CiPA1 initiative [1, 2] aims at developing a new approach to assess the
proarrhythmic potential of new chemical entities. So far, cardiovascular safety
assessment was mainly focused on QT interval prolongation, which is used as a
marker for predicting the risk of a compound to cause potentially fatal ventricu-5
lar cardiac arrhythmia called Torsade de Pointes (TdP). The current preclinical
safety guideline (ICH2 S7B) relies on preclinical electrophysiology tests against
hERG (human-ether-à-go-go Related Gene) and an in vivo QT measurement.
Nevertheless, this approach may increase the number of false positive drugs.
In addition, to increase the likelihood of success, an effective derisking strat-10
egy should evaluate proarrhythmia liability, hemodynamic cardiac contractility
assessment, taking into account both functional and structural aspects of car-
diotoxicity. All this situation has motivated ICH to reconsider approaches to
the evaluation of drug-induced cardiac injuries. To that aim, in silico action po-
tential simulations based on the O’Hara-Rudy model [3] have been integrated in15
the CiPA (Comprehensive In Vitro Proarrhythmia Assay) effort to better assess
human cardiotoxicity risks. A second main component of the CiPA project relies
on stem cell-derived human myocyte studies. Two technologies were suggested
for evaluation, namely the multielectrode array (MEA) and the voltage-sensing
optical (VSO) platforms. However, other emerging techniques exist, such as20
the cardiomyocyte impedance analysis, which proved to be useful to identify
cardiotoxic compounds [4].
In this context, in the present paper, we evaluated the real-time cell analysis
(RTCA) platform, measuring cell impedance, to assess effects on contractility
of cardiomyocytes exposed to a small panel of drugs. By analogy, this approach25
may be compared with the detection and characterization of abnormalities in
ECG signals. Mahmoud et al. [5] reported that the time-frequency distribution
is employed to reveal the exact multicomponent structure of surface electromyo-
gram with the presence of ECG noise and abnormal cardiac signals. Martis et al.
(2014) compared four methods to diagnose ECG abnormalities [6]. They asso-30
ciate two different transforms (wavelet vs cosinus) with statistical techniques of
reduction such as the Principal Component Analysis followed by clustering anal-
ysis involving K-nearest neighbor, decision tree and artificial neural networks.
Since that time, a large spectrum of methods have been tested such as sequential
Bayesian methods [7], multiscale energy and eigenspace approach [8], multires-35
olution time-dependent entropy method [9], signal decomposition model-based
Bayesian approach [10] and continuous wavelet transform [11]. However, sev-
eral main differences may be emphasized between the ECG and cardiomyocyte
impedance analysis. Firstly, PQRST waves do not exist in CI (cell index) sig-
nals and their beating shape may change completely depending on the drugs40
used [12, 13]. Secondly, conversely to usual ECG that are recorded during about
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10s only, CI responses can be measured during one week of experimentation and
generate larger data files to be processed.
MEA, VSO and RTCA platforms are increasingly used for drug discovery
applications. In such a context, large number of molecules can be tested on45
cardiomyocytes and several parameters can be analyzed to assess cardiotoxicity
risks. This computational task is time-consuming and user dependent. Our
objective was to develop an automatic, reliable and fast method to compare the
effects of tested drugs on cell impedance (CI) responses in cardiomyocytes. To
address this issue, we propose a triple-stage method. The first step is based50
on the estimation of five time-variant parameters of CI responses. In a second
phase, a concentration-effect modeling of the five indices is performed and sta-
tistical tests are used to assess the relevance of all variations in comparison with
the control group. Finally, a score of critical effects is proposed to compare the
alteration effects on the CI responses of tested molecules in a new cardio-impact55
scale. The second main intended purpose of this article is to assess the practical
relevance of this new approach applied to real cardiomyocyte impedance data.
This paper is organized as follows. In section 2, the cardiomyocyte impedance
analysis is introduced. Section 3 describes the methodology and the impedance
data corresponding to three molecules are presented in section 4. Finally, as a60
proof of concept, results are discussed with a set of two cardiotoxic and one non-
cardiotoxic compounds to demonstrate the potential of the developed approach
to analyze impedance data in a rapid and reliable way.
2. Cardiomyocyte Impedance assays and summary of Material &
Methods65
The use of electrical impedance to measure cellular processes was first re-
ported by Giaever in 1984, [14, 15]. The xCELLigence platform generating
impedance data has been identified as a powerful and reliable tool in drug
discovery for toxicity and pharmacology studies [16, 17]. All the impedance-
based cell analyzers use the fact that cells have an electrical insulating mem-70
brane. This property comes from its biological composition. Indeed, the cell
membranes are made of phospholipid bilayer, and these lipids act as electri-
cal insulators, [18, 19]. Consequently, when an electrical current generated by
electrodes at the bottom of a well flows into a ion solution, the whole well be-
haves as a variable impedance. The most cells fix on the substrat at the bottom75
of the wells, the most it decreases the current exchange area, increasing the
impedance [18, 20]. This electrical impedance area is modified by multiple pa-
rameters including the number of cells, their size, the way cells communicate
and spread, as well as their substrate adhesion. The data acquisition system
( RTCA cardio) allows to get one numerical value of the cell impedance every80
13ms. The impedance value is finally transformed into dimensionless quantity
entitled Cell-index (CI ) [21, 22, 23]. These CI data generated by this technology
provide two types of information: the viability of cardiomyocytes by examining
the pattern of the impedance signal trend and the cardiomyocytes contractility
by analyzing the periodic pattern of the impedance signals over short periods85
3
called sweeps. As illustrated in Figure 1, the cell impedance sensing is sensitive
enough to monitor cell spreading and clustering as well as beating of the car-
diomyocytes. The spreading of the cells correspond to the increase in CI while
the beating corresponds to the contraction of the cardiomyocytes. Those two
phenomenons differ by amplitude and time constant. Indeed, the spreading is90
a slow and high amplitude process while the cardiac activity is a fast and slow
amplitude process.
The measurement profile is recorded by a station on each well of a 96 wells
plate. The data acquisition was split up into sweeps of 20 secondes recorded
every 5 minutes. In each sweep, the sampling rate is equal to 77.35 Hz, resulting95
in a K = 1547 data-points by sweep. In other terms for control cardiomyocytes,
each sweep contains around 28 beats and for a five-day measurement campaign,
there are about 1440 sweeps to be processed for just one tested well. All the
variables and parameters are listed in Table 1.
Symb. Legend
t ∈ [0, ..., T − 1] moment of measurement of the (t+ 1)-th sweep
k ∈ [0, ...,K − 1] moment of CI measurement within each sweep
yt(k) (k + 1)-th CI value in the t-th sweep
T number of recorded sweeps
K number of time points in a sweep signal
P number of time points in a beating period
tm time of drug administration
d ∈ [1, ..., D] index of the drug concentration
D number of concentration (dose) levels
r ∈ [1, ..., R] index of the replicated well
R number of assay replications
∆t time range of analysis after compound addition
i ∈ [F,A, S, T, I] FASTI index
F (t) beating mean frequency characteristic of the t-th sweep
A(t) beating mean amplitude characteristic of the t-th sweep
S(t) beating pattern characteristic of the t-th sweep
T (t) tth value of the CI trend, mean value of the t-th sweep
I(t) beating irregularity feature of the t-th sweep
Table 1: Description of the parameters and variables used in the proposed statistical signal
processing method
Mouse cardiomyocytes (inducible pluripotent stem cells) were purchased
from Axiogenesis (Cologne, Germany). Famotidine (non-cardiotoxic drug) and
Doxorubicine (cardiotoxic drug in humans) were ordered from Sigma-Aldrich
(Saint-Louis, MO, USA), and Sunitinib (cardiotoxic drug in human) from VWR
(Radnor, PA, USA). The mouse cardiomyocytes were thawed based upon Axio-
genesis standard protocol and seeded on RTCA cardio E-plates at a density of
40 · 103 cells/well. To quantify cell status based on the measured cell-electrode
impedance, a parameter termed cell index (CI) is derived. This index is a time
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Figure 1: Real-time measurement of cardiomyocyte impedance responses. The trend response
is measured the cell index (arbitrary unit) with a sampling period of about 5mn. This in-
creasing trend signal provides information about the cardiomyocyte attachment and spreading
during the experimentation period. Zooming into the cell index response allows to monitor
the contraction of the cardiomyocytes. At each time point ti, a cardio-sweep is measured
during 20s with a sampling rate of 77.35Hz to observe the cardiomyocyte beating pattern. k
is the time index used in each cardio-sweep.
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and sampling frequency dependent quantity described as follows:
CI(tk, fi) = max
i=1,2...k
[
Rcell(tk, fi)
Rbg(fi)
− 1
]
(1)
where Rbg and Rcell are the resistances measured at time tk and frequency fi100
without and in presence of cells respectively [21, 22, 23]. N is the number of
the frequency points at which the impedance is measured. For more details
please refer to Atienzar et al. (2013) [17]. Cell index were monitored for a few
days (usually 2 to 3 days) until all parameters measured were sufficiently stable
(cell index, beating, amplitude, frequency, etc.). E-plates (Roche Diagnostics,105
Vilvoorde, Belgium) were coated, according to the manufacturer’s recommen-
dations. Fibronectin (coating) was purchased from Sigma-Aldrich (Saint-Louis,
MO, USA). Final % dimethyl sulfoxide (DMSO) in each well was 0.1%. Fresh
concentrated stock solutions were prepared in DMSO immediately before first
use and then kept at −20 ◦C for potential retesting. Stock solutions of 1000110
fold the highest concentration were prepared (e.g. 1000 × 10 µM for Famoti-
dine = 10 mM in DMSO) and were used to make the other stock solutions in
100% DMSO. These solutions were diluted 50 times in medium (10 µL stock
in 490 µL of medium: 2% DMSO after dilution). Finally, 10 µL of these in-
termediate solutions were mixed with 190 µL of medium directly in each well115
(dilution 1/20) to reach a final 0.1% DMSO solution. Compounds were added
only once. The mouse cardiomyocytes were exposed to eight concentrations
of the cardiotoxic drugs (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 100 µM) and four con-
centrations of Famotidine (0.1, 1, 10, 100 µM) for 24h. The cell index values
presented in this manuscript were calculated from triplicate values (technical120
replicates) except for the cells exposed to DMSO (n = 6). For all experiments,
the background reading was performed in presence of medium. The cells were
monitored in real-time, at 37 ◦C in a humidified 5% CO2/95% air atmosphere,
using the multi-plate (96-well plate format) xCELLigence platform (Roche Di-
agnostics, Vilvoorde, Belgium). Cell index measurements occurred every 30 min125
until compound addition (usually from t=0 up to t = 2 to 3 days), every minute
after compounds addition for the first 30 min and every 15 min for the last 23.5h.
20 s sweeps were used to collect cell index data at all steps described previously.
Data analysis was performed using the algorithms developed by Cybernano and
presented in this manuscript.130
3. Cardio-Effect Estimation Method
An overview of the cardio-effect estimation method proposed in this article is
presented in Figure 2. This approach is composed of four main steps developed
in the next sections. The main output results generated by each computational
step are indicated on the right part of the figure.135
3.1. Morphological characterization of the CI response alteration
A behavioral characterization of the sweep signals is addressed in this section
to detect and estimate the main changes in the CI responses caused by the
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Figure 2: Overview of the method used to analyze the CI data. The proposed method is
composed of four main steps and provides three major results. The FASTI indices answer
two questions: when do the CI responses change and which parameters are altered? The
concentration-effect analysis informs about which compound concentration significantly affect
the contractibility parameters and viability trend. Finally, a global score is computed to
compare the effects of each tested compound on the cardiomyocyte contractility.
tested molecules. The beating shape depends on cell environment and many
biological factors such as the cell line, cell viability, medium type, compound140
and its concentration. As a consequence many different beating patterns can be
observed as already emphasized by Jonsson et al. in [13] and Xi et al. in [12].
In this context, no model-based approach has been used due to the difficulty
to find out a relevant and general model structure able to accurately fit all the
possible shapes. An alternative solution consists in estimating parameters of the145
beating shape directly from the measured signals. In order to integrate all time
dependent information, we propose to estimate for each sweep five time-indices,
denoted FASTI thereafter :
• Frequency (F): estimate of the mean beating rate per minute in each
sweep;150
• Amplitude (A): average peak-to-trough magnitude in each sweep;
• Shape (S): score characterizing the shape of the mean beating pattern in
each sweep;
• Trend (T): value obtained from the cell index trend signal informing about
the cardiomyocyte viability status, spreading, ...155
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• Irregularity (I): score indicating how much the beat pattern is changing
within each sweep.
Those five characteristics are calculated over the time range: t ∈ [0, ..., T − 1].
For instance, Figures 3, 4 and 5 show the time evolution of the FASTI indices for
the cardiomyocytes exposed to solvent (control condition) and to two molecules:160
Famotidine (negative control compound) and Sunitinib (positive control com-
pound) respectively. The FASTI responses are correlated in the three examined
cases but this correlation is not systematic and not been observed on other
compounds. Moreover, some technical outliers such as peaks may intensify this
effect.165
3.1.1. Frequency
The Frequency characteristics informs about the evolution of the beating
rate (bpm) over the experimentation period [0;T − 1], where T is the number
of cardio sweeps. One usual technique used to estimate F (t) is based on the
detection of peaks. However, this approach is very sensitive to the noise and to
avoid this drawback we propose to compute the maximum peak from the power
spectral density (DSP). The latter is estimated by the Welch estimator based on
the periodogram with windowing and averaging in order to reduce the variance
of the estimates:
F (t) = arg maxSW (f, yt) (2)
SW (f, yt) =
1
P
P−1∑
p=0
1
||w||2
∣∣∣∣∣
M−1∑
m=0
w(m)yt(pS +m)e
−j2πfm
∣∣∣∣∣
2
, (3)
where w ∈ RM is a hamming window, M is the size of the window, and S/M
represents the window overlapping. We choose M = 192 to get enough infor-
mation in each window, and S = 96 to have 50% of overlaying. p ∈ [0, ..., P ]
with P the total number of windows so that pS +M ≤ K, with P = 14.170
3.1.2. Amplitude
As the frequency, the peak-to-trough amplitude of the beating signal is a
complementary parameter characterizing the cardiac activity. This feature is
determined by subtracting the minimum value of the sweep to the maximum
one:
A(t) = max(yt(k))−min(yt(k)). (4)
In practice, each sweep usually contains more than 20 beating waves. To avoid
outliers on the estimation of the response peaks, we build a histogram of the
cell index values and estimate min(yt(k)) and max(yt(k)) as the 3-rd and 97-th
percentiles.175
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Figure 3: Overview of FASTI indices over time from cardiomyocytes exposed to solvent (con-
trol condition, 0.1% DMSO). Except for some rare events due to technical artefacts, the FASTI
indices are stable, no significant change and no irregularity are detected in the 24h timeframe.
The black vertical line indicates the time of the DMSO addition. Data are presented for six
wells.
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Figure 4: Overview of FASTI indices over time from cardiomyocytes exposed to Famotidine
(non-cardiotoxic compound). Cardiomyocytes were exposed to three concentrations of Famo-
tidine: 100nM (light blue), 1µM (medium blue), 10µM (dark blue) for 24h. Compound
addition occurred at tm ≈ 49h as indicated by the black vertical line. The different grade
of blue are not always easy to observe due to the curve overlapping. Nine wells (triplicate
condition for each concentration) of culture are examined. Except for some rare events due
to technical artefacts, the FASTI indices are stable, no significant change and no irregularity
are detected in the 24h timeframe.
10
T 
S 
I 
A 
F 
Figure 5: Overview of FASTI indices over time from cardiomyocytes exposed to Sunitinib
(cardiotoxic compound). Cardiomyocytes were exposed to three concentrations of Sunitinib
(positive control compound): 100nM (light red), 1µM (medium red), 10µM (dark red) for
24h. Compound addition occurred at tm ≈ 53.5h as indicated by the black vertical line. Nine
wells (triplicate condition for each concentration) of culture are examined. We clearly observe
instability of amplitude, frequency and shape, acceleration of irregularities, and a drop of
cardiomyocyte viability a few hours after Sunitinib administration.
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3.1.3. Shape
When the characteristics F (t), A(t) and T (t) of two distinct wells are identi-
cal, their beating pattern can still be different in term of shape. While ECG are
complex signals due to the heart structure, the cell index signal of cardiomy-
ocyte monolayer cultures are usually simpler with generally one main peak. Our
proposal is to capture the sharpness of the signal computed as:
S(t) = 1− 2
A(t)
min
{
T (t)−min(yt(k)),max(yt(k))− T (t)
}
. (5)
When yt(k) is periodic and symmetric (w.r.t its mean value) such as a sinusoidal
signal, S(t) tends to 0. On the contrary, in the absence of peaks (flat signal),
S(t) converges to 1. Otherwise, when yt(k) is not a symmetric beating pattern
its value is between 0 and 1. The more symmetric the signal, the more S(t) is180
closed to 0. As with the A index, a robust estimation procedure is implemented
to avoid any outlier on the computation of min(yt(k)) and max(yt(k)).
3.1.4. Trend
The viability of cardiomyocytes is derived from the CI data. At time t, the
trend (T ) is estimated by the empirical mean value of cell index over the t-th
sweep :
T (t) =
1
K
K−1∑
k=0
yt(k). (6)
3.1.5. Irregularity
The Irregularity time-characteristics I(t) for the tth recorded sweep is a
discrete variable taking three possible values: {0, 1, 2}. If the beating pattern
is regular all along the sweep I(t) = 0 but if it is drastically varying during the
sweep time range then I(t) = 2. The intermediate value I(t) = 1 is associated
with a moderate change of the beating shape. The computation of I(t) relies
on the mean energy of the measured signal:
E(k) =
k+P−1∑
n=k
|yt(n)|2, (7)
where k ∈ [0, ...,K − P − 1] and P is the number of time points in a beating
period. Therefore, by considering a sliding window calculation, E(k) becomes a
new signal providing information about the variation of the mean energy within
the sweep range. For a noise-free periodic signal, E(k) is constant but in practice
the CI values are noisy and E(k) can be described as follows:
E(k) = a+ e, e ∼ N (0, σe), (8)
where the parameter a denotes the mean energy of the current sweep. From185
the likelihood function and the Fisher information of this model, we are able
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to estimate a and σe and their corresponding standard errors. Given those
estimates, the Table 2 describes the algorithm to compute I(t). If one of the
two variation coefficients cva and cvσe are too large it implies that E(k) is likely
not a constant, i.e. yt is irregular. A second irregularity index used to compute190
I(t) is related to the noise-signal ratio R. Three example of irregularity values
are presented in Figure 6. They show the ability of this index to detect different
levels of beating irregularity within a cardio sweep.
No. Step
1 compute R = σ̂e/â
2 compute cva = σ̂a/â
3 compute cvσe = σ̂σe/σ̂e
4 if (cva > 0.05) or (cvσe > 0.05) or (R > s2)
I(t) = 2
5 else if s2 ≤ R < s1
I(t) = 1
6 else
I(t) = 0
end if
Table 2: Algorithm used for the computation of the irregularity characteristic associated with
the tth sweep. s1 ands2 are two thresholds chosen by the user.
3.2. Normalization
For clarity, X(t) is used thereafter to refer to one the four indices: F (t),195
A(t), S(t), T (t) because they received the same processing. Nevertheless, I(t)
is treated separately. To reduce the potential effects of uncontrolled variations
between the wells and the plates, a double-step normalization process is applied
to the previous time-indices.
3.2.1. Time normalization200
The first normalization consists in fixing to zero all the indices at time tm,
i.e.: the time instant just before drug administration.
Xn(t) = X(t)−X(tm − 1), (9)
with t ∈ [tm, · · · , tm+∆t]. tm is selected based on the stability of the parameters
usually obtained two days after cardiomyocyte seeding (time usually required
to have a stabilization of the parameters). The study time frame was fixed to
∆t = 24h.
3.2.2. Normalization205
Since the goal of the study is to compare the drug effect with a control agent
(vehicle compound), indices are centered and reduced as follows:
Xnn(t) =
Xn(t)− µc(t)
σc(t)
(10)
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Figure 6: Examples of cardiomyocytes beating exposed to 33nM of Sunitinib (cardiotoxic
drug). The beating profiles were obtained at three different time instants after its adminis-
tration. They illustrate three distinct values of irregularity. A: I = 0 at t = 65.79h (constant
beating rate during the whole sweep); B: I = 1 at t = 72.93h (prolongation of the beating
period at the beginning of the sweep but the other peak-to-peak periods are constant); C:
I = 2 at t = 124.41h (the beating rate is inconstant during the sweep.
where µc(t) and σc(t) are the empirical mean and standard-deviation of the
control group.
3.3. Concentration-effect Analysis
To analyze how the normalized FASTI indices are changing with respect
to the compound concentrations, a summary of the information contained in
those meta-signals was performed. To that aim, we calculate two statistical
summaries of Xnn, noted SX,1 and SX,2. SX,1 is the root mean square value of
Xnn:
SX,1 =
√√√√ 1
T
T−1∑
t=0
Xnn(t)2. (11)
When SX,1 is near zero, Xnn is close to the reference profile (control). The
second component, SX,2, corresponds to the empirical standard deviation of the
innovation term:
SX,2 =
√√√√ 1
T − 1
T−2∑
t=0
(Xnn(t+ 1)−Xnn(t))2. (12)
14
In other terms, SX,2 estimates the mean magnitude of the abrupt and chaotic
variations of Xnn. When SX,2 is close to zero, the profile of Xnn(t) is regular210
and its value is increasing when Xnn(t) becomes instable. For the irregularity
characteristics I(t), we use the proportion of irregularity of type 1 for SI,1 and
the total proportion of irregularity, that is type 1 and type 2, for SI,2.
At this step, for each well, we have a total 10 statistics, i.e. 2 statistics for 5
indices. Now, we can group them by concentration for each tested compound.
Each condition relative to the compounds is repeated in three different wells
of the same plate. In such a context, statistical tests can be applied for each
concentration level to decide whether significant differences exist between the
tested compounds and the control group. An ANOVA test is used and the latter
relies on the following model:
SX,j(d, r) = β
(j)
X,0 + β
(j)
X,d + ηd,r, ηd,r ∼ N (0, s) (13)
where X ∈ {F,A, S, T} refers to the FAST index, j ∈ {1, 2} is the component
index, r ∈ {1, · · · , R} is the replication index of the assays and d ∈ {1, · · · , D}215
is the d-th concentration level of the tested drug. ηd,r refers to the unexplained
intra-group variability. β(j)X,0 is the mean response of SX,j(0, r) for the null
concentration (d = 0) and β(j)X,d is the mean additive effect of the dose d on
SX,j . Once the parameters estimated, a T-test is performed and its p-value
is used to decide whether or not the effect β(j)X,d of the concentration level d is220
significantly different from 0. In this application, the significance threshold is
fixed to p = 0.01. For the I index, a χ2-test is applied to assess the effect of each
concentration level in comparison with the null-concentration (vehicle) sample.
3.4. Effect scoring and modeling
Based on the results of the previous statistical tests, a score of critical effect
E(d) is calculated for each concentration d of the tested compound on the cell
impedance responses. E(d) is defined as follows:
E(d) =
2∑
j=1
∑
X∈I
1[pX,j,d<0.01] (14)
where I = {F,A, S, T, I}, 1 is the index function and pX,j,d is the p-value asso-225
ciated with the statistical test of significance for the statistics SX,j . E ranges
from 0 (no effect) to 10 (strong effect). If the concentration effect is significant,
a median-effect concentration (EC50) is estimated by fitting a Hill model to
the values of E(d) [24]. This median-effect concentration will be used to com-
pare the effects of compounds on the cardiomyocyte contractility. Nevertheless,230
when the score variation is abrupt, e.g. from 0 to 10 between two successive
tested concentrations, the EC50 estimation based on the Hill model may be too
uncertain. In that case, the experimenter is advised to test new concentrations
within the appropriate variation range.
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4. Effect of Test Compounds on Cardiomyocytes235
In this section we present experimental results of the proposed statistical
signal processing method applied to in vitro data obtained from cell impedance
analysis. The objective was to assess the suitability of the proposed methodol-
ogy to correctly discriminate the effects of Famotidine (non-cardiotoxic drug),
Sunitinib and Doxorubicine (cardiotoxic drug in humans).240
The global effect scores (E(d)), Hill model response (EC50 estimation) and
the ten FASTI summary statistics (SX,1 and SX,2 in section 3.3) are presented
in Figures 7,8 and 9 for the three tested compounds, respectively. Maximum
therapeutic plasma concentrations of Sunitinib and Doxorubicin were obtained
from Pharmapendium3.245
For Famotidine, we clearly observe no significant effect on the cardiomy-
ocytes up to 100 µM equivalent to ca. 50 fold the maximum concentration in
human blood (Cmax). In humans, Famotidine (0.5 mg kg−1) has a Cmax value of
0.64 µg mL−1 (i.e. 1.90 µM) [25]. The global effect score remains under 1 in the
tested concentration range and no significant variation of any FASTI index was250
detected. Some red dots appear in low concentration (100 µM) of Famotidine for
SA,1 but those not significant results can be ignored as not reproduced at higher
concentrations. Although some cases of QT prolongation have been reported in
humans (not in animals) [26], Famotidine does not inhibit hERG nor increases
cardiac action potential in vitro [27]. Moreover, it does not affect cardiac con-255
tractility or heart rate in animals or in humans [28]. Therefore, the low global
effect score well reflects the overall safe cardiac properties of Famotidine.
In the second example, Sunitinib was classified as a cardiotoxic drug. Its
global score and FASTI indices show a significant alteration of the beating
activity with a median effect concentration estimated to be EC50=1.3 µM. The260
main cardiac effect of sunitinib is hypertension and left ventricular dysfunction,
which has been reported in up to 12% metastatic carcinoma patients treated
with this drug [29]. Bradycardia or QT prolongation are more rarely observed.
Cmax of Sunitinib has been reported to be 0.253 µM in humans (Guo et al. [4]).
The ratio between the EC50 and Cmax is only ca. 5 fold (1.3/0.253).265
The last example deals with doxorubicin, an anthracycline drug widely used
to treat a variety of tumours. Doxorubicin is a structural cardiotoxicant caus-
ing QT prolongation without acute cardiac ion channel such as hERG liabil-
ity [30, 31]. It was recently proposed that doxorubicin-induced QT prolonga-
tion could be due to the direct inhibition of IKs (a slowly activating component270
of delayed rectifier K+ channel) [30]. This examples illustrates the danger of
neglecting I(Ks) in favor of hERG screening alone, for early preclinical testing
for possible induction of torsade de pointes [30]. Doxorubicin has a maximum
therapeutic plasma concentration of 15.34 µM [31, 32]. In the present study, a
EC50 of 9.7 µM is reported in mouse cardiomyocytes, which is even below the275
clinical efficacious plasma concentration of doxorubicin. In other words, these
3https://www.pharmapendium.com
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results suggest that doxorubicin has the potential to induce cardiotoxicity at
the efficacious concentration in human.
5. Conclusion
In the context of the CiPA initiative, this paper addresses the identifica-280
tion problem of new biosignal markers able to predict the risk of molecules to
potentially disturb the contractility of cardiomyocytes. The proposed and de-
veloped approach deals with a statistical signal processing method that provides
to biologists three levels of information.
It firstly computes five indices informing about the time variations of irreg-285
ularity, frequency, amplitude and shape of beatings but also an estimation of
the cardiomyocyte viability. That first step allows to speed up the analysis of
cardiomyocyte RTCA data. Indeed, instead of analyzing individual time points,
the FASTI indices bring a global overview of the cardiomyocyte behavioral char-
acteristics and allow to quickly identify subtle changes over time.290
In a second step, two summary statistics of the FASTI indices are computed
over all the experimental time range and are used to test dose response relation-
ship. Those two additional attributes provide clarifications about the threshold
concentration effects of each molecule. The Student’s t-test is used to detect
the statistical significance of each concentration effect with respect to a given295
control.
A global cardio-effect score is finally proposed to compare the alteration
effects of the tested pharmaceutical agents on the cardiomyocyte contractility.
To this aim, we have proposed a new cardio-effect scale graduated from 0 (no
influence) to 10 (critical effect). This approach allows thus to compare different300
compounds on the same diagram.
To assess its practical relevance, the proposed approach was applied to the
cardiomyocyte impedance data of three known compounds. Compared to recent
results, these preliminary results have corroborated the ability of the proposed
method to efficiently discriminate the effects of the tested drugs. The main ad-305
vantage of this approach is to provide rapid and reliable analysis of complex sig-
nals. The complete approach was implemented on a web-platform: i-CardioTM4
and is now available for all users of the RTCA technologies.
Finally, to confirm the validity of the proposed approach, the next step will
evaluate this new method to a larger batch of molecules. In particular, we will310
address the potential correlations between the results provided by such data-
driven modeling approaches and the underlying biological phenomena associated
with cardiotoxicity.
4https://www.cybernano.eu/i-cardio
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Figure 7: Summary of concentration-effects induced by Famotidine on mouse cardiomyocytes.
A. Global effect scores. Minimum score (0) means that the FASTI parameters are not signif-
icantly different compared to control data (cardiomyocytes exposed to 0.1% DMSO). A score
of 10 corresponds to severe effects often manifested by a beating arrest of the cardiomyocytes.
Highest score for Famotidine is 1. B. Estimated EC50 value (no data reported up to 100µM).
C. FASTI indices: blue dots correspond to control values, green dots indicate no significant
change w.r.t. control and red dots point out significant changes compared to control data.
Each time red dots are detected, the global effect score is increased by one unit.
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Figure 8: Summary of concentration-effects induced by Sunitinib on mouse cardiomyocytes. A.
Global effect scores. Minimum score (0) means that the FASTI parameters are not significantly
different compared to control data (cardiomyocytes exposed to 0.1% DMSO). A score of 10
corresponds to severe effects often manifested by a beating arrest of the cardiomyocytes.
Highest score for Sunitinib is 10. B. EC50 value is estimated between 1 µM and 3 µM. Since
the variation of the global score is abrupt, the EC50 estimated value provided by the Hill
model (1.3µM) is uncertain. C. FASTI indices: blue dots correspond to control values, green
dots indicate no significant change w.r.t. control and red dots point out significant changes
compared to control data. Each time red dots are detected, the global effect score is increased
by one unit.
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Figure 9: Summary of concentration-effects induced by Doxorubicine on mouse cardiomy-
ocytes. A. Global effect scores. Minimum score (0) means that the FASTI parameters are
not significantly different compared to control data (cardiomyocytes exposed to 0.1% DMSO).
A score of 10 corresponds to severe effects often manifested by a beating arrest of the car-
diomyocytes. Highest score for Doxorubicine is 8. B. Estimated EC50 values: 9.7 µM for
Doxorubicine. C. FASTI indices: blue dots correspond to control values, green dots indicate
no significant change w.r.t. control and red dots point out significant changes compared to
control data. Each time red dots are detected, the global effect score is increased by one unit.
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